Pet/ct with sodium18f-fluoride for management of patients with prostate cancer

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 531-533

  Segall, George M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; ETIDRONIC ACID TC 99M; SODIUM FLUORIDE F 18;

BONE METASTASIS; BONE SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE METASTASIS; TREATMENT PLANNING;

HUMANS; MALE; MEDICAL ONCOLOGY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SODIUM FLUORIDE;

EID: 84901380833     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.133546     Document Type: Review

References (14)

1. Cancer facts and figures 2014. American Cancer Society. http://www.cancer.org/acs/groups/content/@research/documents/document/ acspc-041770. pdf. Accessed February 13, 2014.
2. Roehrborn CG, Black LK. The economic burden of prostate cancer. BJU Int. 2011;108:806-813.
3. Guidelines NCCN. Prostate cancer 1.2014. National Comprehensive Cancer Center. http://www. nccn.org/professionals/physician-gls/pdf/prostate. pdf. Accessed February 13, 2014.
4. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and 18F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804.
5. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18Ffluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
6. Tateishi U, Morita S, Taguri M, et al. A metaanalysis of 18F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523-531.
7. National Coverage Determination (NCD) for positron emission tomography (NaF-18) to identify bone metastasis of cancer (220.6.19). Centers for Medicare and Medicaid Services. http://www.cms. gov/medicare-coverage-database/details/ ncddetails. aspx?NCDId5336&ncdver51&NCAId5 233& NcaName5Positron1Emission1Tomography1 (NaF518)1to1Identify1Bone1Metastasis1of1 Cancer&IsPopup5y&bc5AAAAAAAACAAAAA% 3D%3D&. Accessed February 13, 2014.
8. Report MS. National Oncologic PET Registry. http://www.cancerpetregistry. org/status.htm. Accessed February 13, 2014.
9. Hillner BE, Siegel BA, Hanna L, Duan F, Shields AF, Coleman RE. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the National Oncologic PET Registry. J Nucl Med. 2014;55:574-581.
10. Choline C-11 injection. Full prescribing information. United States Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/203155s000lbl.pdf. Accessed February 13, 2014.
11. Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81:e893-e896.
12. Poulsen MH, Petersen H, Høilund-Carlsen PF, et al. Spine metastases in prostate cancer: comparison of [99mTc]MDP wholebody bone scintigraphy, [18F] choline PET/CT, and [18F]NaF PET/CT. BJU Int. December 9, 2013 [Epub ahead of print].
13. Von Eyben FE, Kairemo K. Meta-analysis of 11Ccholine and 18F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun. 2014;35:221-230.
14. Jadvar H. Molecular imaging of prostate cancer with PET. J Nucl Med. 2013;54:1685-1688.